Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Tobacco Use Disorder 1 Stress Disorders, Post-Traumatic 1 Smoking Cessation 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Digestive System Abnormalities 1 Depression 1 Anxiety Disorders 1 Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 59 Cisplatin 45 Cetuximab 29 Radiotherapy 26 Carboplatin 24 Docetaxel 17 Paclitaxel 16 Nivolumab 16 Surveys and Questionnaires 15 Radiotherapy, Intensity-Modulated 13 Fluorouracil 12 Drug Therapy 12 Blood Specimen Collection 11 Standard of Care 8 tislelizumab 7 cemiplimab 6 atezolizumab 6 Radiation 6 Chemoradiotherapy 6 toripalimab 5 Cyclophosphamide 5 130-nm albumin-bound paclitaxel 5 nimotuzumab 4 fludarabine 4 durvalumab 4 dostarlimab 4 Surgical Procedures, Operative 4 Afatinib 4 palbociclib 3 niraparib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Head and Neck Neoplasms × Amyloid × 1 year × Clear all

NCT05997329 2025-09-08

NUTREAT

University of Oslo

Phase NA Active not recruiting

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡